We are live on ! Find out more
DNTH icon

Dianthus Therapeutics
DNTH

93 hedge funds and large institutions have $139M invested in Dianthus Therapeutics in 2022 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 19 increasing their positions, 30 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.02% more ownership

Funds ownership: 5.07% → 5.09% (+0.02%)

6% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 16

1% less funds holding

Funds holding: 94 → 93 (-1)

34% less capital invested

Capital invested by funds: $211M → $139M (-$72.5M)

37% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 30

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

50% less call options, than puts

Call options by funds: $1K | Put options by funds: $2K

Holders
93
Holders Change
-1
Holders Change %
-1.06%
% of All Funds
1.47%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
15
Increased
19
Reduced
30
Closed
16
Calls
$1K
Puts
$2K
Net Calls
-$1K
Net Calls Change
+$48K

Top Buyers

1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$6.02M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$4.46M
3
Millennium Management
Millennium Management
New York
+$2.46M
4
WP
Woodline Partners
California
+$1.82M
5
DTC
Deep Track Capital
Connecticut
+$1.67M

Top Sellers

1
ACM
Aquilo Capital Management
California
-$14M
2
CC
Casdin Capital
New York
-$3.85M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.54M
4
GGHC
Gilder Gagnon Howe & Co
New York
-$996K
5
Truist Financial
Truist Financial
North Carolina
-$566K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
76
Citigroup
New York
$7K -$24K -439 -75%
SIAP
77
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
$6K – – –
Wells Fargo
78
Wells Fargo
California
$5K -$36.2K -663 -86%
AIP
79
Ameritas Investment Partners
Nebraska
$5K – – –
BDWM
80
Brewin Dolphin Wealth Management
Ireland
$4K – – –
SOW
81
State of Wyoming
Wyoming
$4K +$109 +2 +2%
SO
82
STRS Ohio
Ohio
$3K – – –
UB
83
UMB Bank
Missouri
$2K +$2.51K +46 New
Fidelity Investments
84
Fidelity Investments
Massachusetts
$1K -$2.54M -46,537 -100%
CAPTRUST Financial Advisors
85
CAPTRUST Financial Advisors
North Carolina
$1K – – –
ACM
86
Aquilo Capital Management
California
– -$14M -197,193 Closed
Truist Financial
87
Truist Financial
North Carolina
– -$566K -7,989 Closed
HF
88
HRT Financial
New York
– -$217K -3,068 Closed
DCM
89
Dupont Capital Management
Delaware
– -$122K -1,722 Closed
OC
90
Oppenheimer & Co
New York
– -$89K -1,250 Closed
Walleye Trading
91
Walleye Trading
New York
– -$81K -1,143 Closed
Squarepoint
92
Squarepoint
New York
– -$80K -1,134 Closed
DU
93
Delphia (USA)
Ontario, Canada
– -$68K -962 Closed
EGM
94
Engineers Gate Manager
New York
– -$67K -948 Closed
Vontobel Holding
95
Vontobel Holding
Switzerland
– -$66K -924 Closed
Susquehanna International Group
96
Susquehanna International Group
Pennsylvania
– -$46K -652 Closed
JF
97
Jump Financial
Illinois
– -$45K -641 Closed
UBS Group
98
UBS Group
Switzerland
– -$32K -451 Closed
Russell Investments Group
99
Russell Investments Group
United Kingdom
– -$9K -134 Closed
HPC
100
HM Payson & Co
Maine
– -$4K -63 Closed
1 2 3
4
5

DNTH Hedge Fund Activity: Q1 2022 in Review

93 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q1 2022, worth a combined $139M — down 34% from $211M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of DNTH and 15 opened new positions — a net loss of 1 holder — while 30 trimmed existing stakes and 19 added.

The largest buyer was Janus Henderson Group, adding an estimated $6.02M. The largest seller was Aquilo Capital Management, exiting entirely with an estimated $14M sold.

  • 93 institutional investors held Dianthus Therapeutics (DNTH) as of Q1 2022, down from 94 in Q4 2021.
  • Funds reported $139M of Dianthus Therapeutics stock for Q1 2022, down 34% quarter-over-quarter.
  • 15 funds opened new Dianthus Therapeutics positions in Q1 2022 and 16 closed out, a net change of -1 holder.
  • The largest Dianthus Therapeutics buyer in Q1 2022 was Janus Henderson Group, an estimated $6.02M added.
  • The largest Dianthus Therapeutics seller in Q1 2022 was Aquilo Capital Management, an estimated $14M sold.

Based on aggregated 13F filings for Q1 2022.